Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team Webcast (2026)
Availability
On-Demand
Expires on May 22, 2027
Cost
$0.00
Credit Offered
1.5 AMA PRA Category 1 Credit Credits
1.5 Participation Credits


New for 2026, AUA2026 Focus on: are series of accredited sessions, offering an in-depth exploration of key clinical topics aligned with AUA’s ongoing needs assessments. The format allows for a deeper dive into each topic, exploring clinical advances, reviewing the latest evidence-based guidelines and discussing application into clinical practice. Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team will offer education and updates to the urology care team on the complex management of bladder cancer patients and the latest advancements in NMIBC.

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

  • AstraZeneca
  • ImmunityBio
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • UroGen Pharma, Inc.
After participating in this CME activity, participants will be able to:
  1. Analyze emerging data in NMIBC and guideline updates to evaluate the impact of disease recurrence and treatment-related complications on current care pathways and patient outcomes.
  2. Apply guideline-driven risk stratification in order to identify and select appropriate patients with high-risk NMIBC for optimal therapy sequencing and escalation of care.
  3. Implement strategies for safe and effective integration of novel intravesical and systemic immunotherapies to strengthen multidisciplinary collaboration and shared decision-making between urology and medical oncology.
  4. Develop patient-centered, evidence-informed care plans using guideline updates and real-world case examples, in order to address unmet needs, reduce recurrence risk, and improve quality of life for patients with NMIBC.
FACULTY DISCLOSURES
Name Company Name Relationship Type End Date
Janet Kukreja, MD No relevant financial relationships to disclose
Elizabeth Kessler, MD Pfizer Scientific Study or Trial Current
Merck Scientific Study or Trial Current
Johnson & Johnson Scientific Study or Trial Current
Bristol Myers Squibb Scientific Study or Trial Current
Suzanne B. Merrill, MD Photocure Consultant or Advisor Current
Johnson & Johnson Meeting Participant or Lecturer Current
EnGene Consultant or Advisor Current
UroGen Meeting Participant or Lecturer Current
Pfizer Consultant or Advisor Current
Astellas Meeting Participant or Lecturer Current
Mary E. Westerman, MD, FACS No relevant financial relationships to disclose


EDUCATION COUNCIL DISCLOSURES
Education Council 2025

COI REVIEW WORK GROUP DISCLOSURES
COI Review Work Group 2025


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2026
Expiration Date: May, 2027

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

 


AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.